Oppenheimer Sticks to Their Hold Rating for Cooper Co (COO)

By Carrie Williams

In a report released today, Steven Lichtman from Oppenheimer maintained a Hold rating on Cooper Co (COOResearch Report), with a price target of $282. The company’s shares opened today at $263.49.

Lichtman wrote:

“Cooper’s F4Q18 sales of $651.5M (up 9% year-over-year, pro forma) topped our/ Street’s $644M/$645M estimates. The beat was driven by outperformance in CVI that continued to be led by daily Silicon Hydrogel; CSI was a touch below with strong performance in PARAGUARD offset by lower fertility. EPS of $2.87 lagged our/Street’s $2.95/$2.96E on incremental costs associated with distribution center upgrade and legacy product write-offs (combined -150bps/-$0.14 impact on GM/EPS). FY19 sales guidance of $2.6-2.66B assumes mid- to high-single-digit, PF growth and $61M negative FX. EPS guidance was below Street on lower near-term GM headwinds and FX. COO noted overall investments in CVI key accounts and in Paraguard are driving increased momentum in those businesses.”

According to TipRanks.com, Lichtman is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -8.0% and a 46.9% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Motus Gi Holdings Inc.

Cooper Co has an analyst consensus of Strong Buy, with a price target consensus of $295.71.

See today’s analyst top recommended stocks >>

Cooper Co’s market cap is currently $13.6B and has a P/E ratio of 109.29. The company has a Price to Book ratio of 4.22.

Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. Most recently, in September 2018, Thomas A. Bender, a Director at COO sold 7,150 shares for a total of $1,925,855.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

The Cooper Cos, Inc. operates as a medical device company. It operates through the following business units: Cooper Vision and Cooper Surgical. The Cooper Vision business unit brings a refreshing perspective on vision care with a commitment to crafting quality lenses for contact lens wearers.